Niadyne Inc.
This article was originally published in Start Up
Executive Summary
Niadyne Inc.'s scientific founders have devoted their academic careers to the biological causes of skin cell injury and methods for its repair. The company has developed nutrient-based compounds to combat the DNA damage that leads to deterioration in skin's appearance, as well as a topical system to deliver them. Niadyne's initial products will be marketed as cosmeceuticals, but it aims to pursue longer-term therapeutic interests in wound healing and heart disease.
You may also be interested in...
Skin Repair
A handful of start-ups hopes to fill the cracks in the fragmented market for skin repair. Their approaches vary widely; British start-up Renovo has a pharmaceutical approach to the prevention of scarring. Reconstructive Technologies believes that the best replacement for skin is skin itself; it has developed a bioreactor that accelerates the growth of autograft skin, with both {in vivo} and {in vitro} systems. Artecel Sciences will use adipose-derived stromal cells in cosmesis and hematopoietic support. Niadyne 's platform of unique formulations of niacin lend themselves to a variety of applications, in cosmeceuticals and in cardiovascular disease.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)